Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
Total Valuation
Vivos Therapeutics has a market cap or net worth of $11.64M. The enterprise value is $16.48M.
Market Cap$11.64M
Enterprise Value$16.48M
Share Statistics
Vivos Therapeutics has 13,486,006 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,486,006
Owned by Insiders10.04%
Owned by Institutions0.55%
Financial Efficiency
Vivos Therapeutics’s return on equity (ROE) is 14.25 and return on invested capital (ROIC) is -123.14%.
Return on Equity (ROE)14.25
Return on Assets (ROA)-0.84
Return on Invested Capital (ROIC)-123.14%
Return on Capital Employed (ROCE)-2.81
Revenue Per Employee160.03K
Profits Per Employee-194.77K
Employee Count109
Asset Turnover0.69
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vivos Therapeutics is ―. Vivos Therapeutics’s PEG ratio is 0.14.
PE Ratio―
PS Ratio1.20
PB Ratio-14.00
Price to Fair Value-14.00
Price to FCF-1.18
Price to Operating Cash Flow-0.51
PEG Ratio0.14
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 17.44M and earned -21.23M in profits. Earnings per share was -2.06.
Revenue17.44M
Gross Profit10.54M
Operating Income-19.89M
Pretax Income-21.23M
Net Income-21.23M
EBITDA-18.59M
Earnings Per Share (EPS)-2.06
Cash Flow
In the last 12 months, operating cash flow was -15.26M and capital expenditures -893.00K, giving a free cash flow of -16.16M billion.
Operating Cash Flow-15.26M
Free Cash Flow-16.16M
Free Cash Flow per Share-1.20
Dividends & Yields
Vivos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change-67.84%
50-Day Moving Average1.36
200-Day Moving Average2.79
Relative Strength Index (RSI)36.31
Average Volume (3m)421.86K
Important Dates
Vivos Therapeutics upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateApr 15, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Vivos Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -906.17%
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.46
Net Debt to EBITDA-0.62
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vivos Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vivos Therapeutics EV to EBITDA ratio is -1.74, with an EV/FCF ratio of -1.84.
EV to Sales1.85
EV to EBITDA-1.74
EV to Free Cash Flow-1.84
EV to Operating Cash Flow-2.12
Balance Sheet
Vivos Therapeutics has $2.03M in cash and marketable securities with $13.50M in debt, giving a net cash position of -$11.47M billion.
Cash & Marketable Securities$2.03M
Total Debt$13.50M
Net Cash-$11.47M
Net Cash Per Share-$0.85
Tangible Book Value Per Share-$1.38
Margins
Gross margin is 60.45%, with operating margin of -114.05%, and net profit margin of -121.71%.
Gross Margin60.45%
Operating Margin-114.05%
Pretax Margin-121.71%
Net Profit Margin-121.71%
EBITDA Margin-106.55%
EBIT Margin-114.05%
Analyst Forecast
The average price target for Vivos Therapeutics is $2.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.13
Price Target Upside-4.28% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast16.05%
EPS Growth Forecast27.95%